Aprotinin Reduces Interleukin-8 Production and Lung Neutrophil Accumulation After Cardiopulmonary Bypass

Pulmonary neutrophil entrapment and resultant oxidative injury is thought to be the primary mechanism of cardiopulmonary bypass (CPB) induced lung injury.Interleukin-8 (IL-8), a potent neutrophil chemoattractant induced by cytokines, including tumor necrosis factor-alpha (TNF), is found in increased...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anesthesia and analgesia 1996-10, Vol.83 (4), p.696-700
Hauptverfasser: Hill, Gary E., Pohorecki, Roman, Alonso, Anselmo, Rennard, Stephen I., Robbins, Richard A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 700
container_issue 4
container_start_page 696
container_title Anesthesia and analgesia
container_volume 83
creator Hill, Gary E.
Pohorecki, Roman
Alonso, Anselmo
Rennard, Stephen I.
Robbins, Richard A.
description Pulmonary neutrophil entrapment and resultant oxidative injury is thought to be the primary mechanism of cardiopulmonary bypass (CPB) induced lung injury.Interleukin-8 (IL-8), a potent neutrophil chemoattractant induced by cytokines, including tumor necrosis factor-alpha (TNF), is found in increased concentrations in bronchial alveolar lavage fluid (BALF) in lung inflammation. Since aprotinin reduces TNF release during CPB, the effects of aprotinin on BALF IL-8 concentrations and neutrophil levels were determined after CPB in adult humans. Study patients were equally divided into a control group (n = 8, Group 1) and an aprotinin treated group (n = 8, Group 2). In vitro neutrophil chemotaxis was done with volunteer neutrophils using three different chemoattractants1) N-formyl-1-methionyl-1-leucyl-1-phenylalanine (FMLP); 2) the supernatant of a human bronchial epithelial cell culture line, A549, after 24 h of TNF stimulation with or without aprotinin or N-alpha-tosyl-L-lysine chloromethyl ketone (TLCK) (a potent protease inhibitor), and 3) BALF. Aprotinin treatment significantly (P < 0.05) reduced post-CPB BALF IL-8 concentrations and percentage of neutrophils. In vitro, BALF from Group 1 had significantly greater chemotactic ability when compared with Group 2. The TNF stimulated A549 cell culture supernatant had significantly (P < 0.05) greater chemotactic ability than control supernatant, while aprotinin and TLCK significantly (P < 0.05) reduced this chemotactic ability. These results demonstrate that aprotinin blunts IL-8 production and reduces neutrophil lung accumulation post-CPB.(Anesth Analg 1996;83:696-700)
doi_str_mv 10.1097/00000539-199610000-00006
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78368292</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>78368292</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5296-9cf81ee9f959de9c84ce9045155caa49d13517f5b9d53d25d59c7607b34920943</originalsourceid><addsrcrecordid>eNp1kV9vFCEUxYnR1LX6EUx4ML6NwjDMcB_XTdUmm7Zp9JmwwLhYBkYY0vTby3bXfZMHyD33d_hzQAhT8okSGD6Tw-AMGgrQ00PRHKb-BVpR3vbNwEG8RKsqsaYFgNfoTc6_a0mJ6C_QhRCMMsJXaL-eU1xccAHfW1O0zfg6LDZ5Wx5caAS-S7HKi4sBq2DwtoRf-MaWJcV57zxea12m4tUzsB6rE29UMi7OxU8xqPSEvzzNKue36NWofLbvTusl-vn16sfme7O9_Xa9WW8bzVvoG9CjoNbCCByMBS06bYF0nHKulerAUMbpMPIdGM5Myw0HPfRk2LEOWgIdu0Qfj_vWd_0pNi9ycllb71WwsWQ5CNaLFtoKiiOoU8w52VHOyU31wpISeQhZ_gtZnkN-lvpqfX86o-wma87GU6q1_-HUV1krPyYVtMtnjLV0GDipWHfEHqOvweUHXx5tknur_LKX__ti9hcGvJRd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>78368292</pqid></control><display><type>article</type><title>Aprotinin Reduces Interleukin-8 Production and Lung Neutrophil Accumulation After Cardiopulmonary Bypass</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Journals@Ovid Complete</source><creator>Hill, Gary E. ; Pohorecki, Roman ; Alonso, Anselmo ; Rennard, Stephen I. ; Robbins, Richard A.</creator><creatorcontrib>Hill, Gary E. ; Pohorecki, Roman ; Alonso, Anselmo ; Rennard, Stephen I. ; Robbins, Richard A.</creatorcontrib><description>Pulmonary neutrophil entrapment and resultant oxidative injury is thought to be the primary mechanism of cardiopulmonary bypass (CPB) induced lung injury.Interleukin-8 (IL-8), a potent neutrophil chemoattractant induced by cytokines, including tumor necrosis factor-alpha (TNF), is found in increased concentrations in bronchial alveolar lavage fluid (BALF) in lung inflammation. Since aprotinin reduces TNF release during CPB, the effects of aprotinin on BALF IL-8 concentrations and neutrophil levels were determined after CPB in adult humans. Study patients were equally divided into a control group (n = 8, Group 1) and an aprotinin treated group (n = 8, Group 2). In vitro neutrophil chemotaxis was done with volunteer neutrophils using three different chemoattractants1) N-formyl-1-methionyl-1-leucyl-1-phenylalanine (FMLP); 2) the supernatant of a human bronchial epithelial cell culture line, A549, after 24 h of TNF stimulation with or without aprotinin or N-alpha-tosyl-L-lysine chloromethyl ketone (TLCK) (a potent protease inhibitor), and 3) BALF. Aprotinin treatment significantly (P &lt; 0.05) reduced post-CPB BALF IL-8 concentrations and percentage of neutrophils. In vitro, BALF from Group 1 had significantly greater chemotactic ability when compared with Group 2. The TNF stimulated A549 cell culture supernatant had significantly (P &lt; 0.05) greater chemotactic ability than control supernatant, while aprotinin and TLCK significantly (P &lt; 0.05) reduced this chemotactic ability. These results demonstrate that aprotinin blunts IL-8 production and reduces neutrophil lung accumulation post-CPB.(Anesth Analg 1996;83:696-700)</description><identifier>ISSN: 0003-2999</identifier><identifier>EISSN: 1526-7598</identifier><identifier>DOI: 10.1097/00000539-199610000-00006</identifier><identifier>PMID: 8831305</identifier><identifier>CODEN: AACRAT</identifier><language>eng</language><publisher>Hagerstown, MD: International Anesthesia Research Society</publisher><subject>Adult ; Aged ; Aprotinin - therapeutic use ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Bronchi - pathology ; Bronchoalveolar Lavage Fluid - immunology ; Cardiopulmonary Bypass - adverse effects ; Cell Culture Techniques ; Chemotactic Factors - antagonists &amp; inhibitors ; Chemotaxis, Leukocyte - drug effects ; Culture Media, Conditioned ; Hemostatics - therapeutic use ; Humans ; Interleukin-8 - analysis ; Interleukin-8 - antagonists &amp; inhibitors ; Leukocyte Count - drug effects ; Lung - drug effects ; Lung - pathology ; Medical sciences ; Middle Aged ; N-Formylmethionine Leucyl-Phenylalanine - pharmacology ; Neutrophil Activation - drug effects ; Neutrophils - drug effects ; Neutrophils - pathology ; Pharmacology. Drug treatments ; Pneumonia - immunology ; Protein Synthesis Inhibitors - pharmacology ; Tosyllysine Chloromethyl Ketone - pharmacology ; Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>Anesthesia and analgesia, 1996-10, Vol.83 (4), p.696-700</ispartof><rights>1996 International Anesthesia Research Society</rights><rights>1996 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5296-9cf81ee9f959de9c84ce9045155caa49d13517f5b9d53d25d59c7607b34920943</citedby><cites>FETCH-LOGICAL-c5296-9cf81ee9f959de9c84ce9045155caa49d13517f5b9d53d25d59c7607b34920943</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;NEWS=n&amp;CSC=Y&amp;PAGE=fulltext&amp;D=ovft&amp;AN=00000539-199610000-00006$$EHTML$$P50$$Gwolterskluwer$$H</linktohtml><link.rule.ids>314,776,780,4595,27901,27902,65206</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=3217750$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8831305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hill, Gary E.</creatorcontrib><creatorcontrib>Pohorecki, Roman</creatorcontrib><creatorcontrib>Alonso, Anselmo</creatorcontrib><creatorcontrib>Rennard, Stephen I.</creatorcontrib><creatorcontrib>Robbins, Richard A.</creatorcontrib><title>Aprotinin Reduces Interleukin-8 Production and Lung Neutrophil Accumulation After Cardiopulmonary Bypass</title><title>Anesthesia and analgesia</title><addtitle>Anesth Analg</addtitle><description>Pulmonary neutrophil entrapment and resultant oxidative injury is thought to be the primary mechanism of cardiopulmonary bypass (CPB) induced lung injury.Interleukin-8 (IL-8), a potent neutrophil chemoattractant induced by cytokines, including tumor necrosis factor-alpha (TNF), is found in increased concentrations in bronchial alveolar lavage fluid (BALF) in lung inflammation. Since aprotinin reduces TNF release during CPB, the effects of aprotinin on BALF IL-8 concentrations and neutrophil levels were determined after CPB in adult humans. Study patients were equally divided into a control group (n = 8, Group 1) and an aprotinin treated group (n = 8, Group 2). In vitro neutrophil chemotaxis was done with volunteer neutrophils using three different chemoattractants1) N-formyl-1-methionyl-1-leucyl-1-phenylalanine (FMLP); 2) the supernatant of a human bronchial epithelial cell culture line, A549, after 24 h of TNF stimulation with or without aprotinin or N-alpha-tosyl-L-lysine chloromethyl ketone (TLCK) (a potent protease inhibitor), and 3) BALF. Aprotinin treatment significantly (P &lt; 0.05) reduced post-CPB BALF IL-8 concentrations and percentage of neutrophils. In vitro, BALF from Group 1 had significantly greater chemotactic ability when compared with Group 2. The TNF stimulated A549 cell culture supernatant had significantly (P &lt; 0.05) greater chemotactic ability than control supernatant, while aprotinin and TLCK significantly (P &lt; 0.05) reduced this chemotactic ability. These results demonstrate that aprotinin blunts IL-8 production and reduces neutrophil lung accumulation post-CPB.(Anesth Analg 1996;83:696-700)</description><subject>Adult</subject><subject>Aged</subject><subject>Aprotinin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Bronchi - pathology</subject><subject>Bronchoalveolar Lavage Fluid - immunology</subject><subject>Cardiopulmonary Bypass - adverse effects</subject><subject>Cell Culture Techniques</subject><subject>Chemotactic Factors - antagonists &amp; inhibitors</subject><subject>Chemotaxis, Leukocyte - drug effects</subject><subject>Culture Media, Conditioned</subject><subject>Hemostatics - therapeutic use</subject><subject>Humans</subject><subject>Interleukin-8 - analysis</subject><subject>Interleukin-8 - antagonists &amp; inhibitors</subject><subject>Leukocyte Count - drug effects</subject><subject>Lung - drug effects</subject><subject>Lung - pathology</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>N-Formylmethionine Leucyl-Phenylalanine - pharmacology</subject><subject>Neutrophil Activation - drug effects</subject><subject>Neutrophils - drug effects</subject><subject>Neutrophils - pathology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia - immunology</subject><subject>Protein Synthesis Inhibitors - pharmacology</subject><subject>Tosyllysine Chloromethyl Ketone - pharmacology</subject><subject>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>0003-2999</issn><issn>1526-7598</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kV9vFCEUxYnR1LX6EUx4ML6NwjDMcB_XTdUmm7Zp9JmwwLhYBkYY0vTby3bXfZMHyD33d_hzQAhT8okSGD6Tw-AMGgrQ00PRHKb-BVpR3vbNwEG8RKsqsaYFgNfoTc6_a0mJ6C_QhRCMMsJXaL-eU1xccAHfW1O0zfg6LDZ5Wx5caAS-S7HKi4sBq2DwtoRf-MaWJcV57zxea12m4tUzsB6rE29UMi7OxU8xqPSEvzzNKue36NWofLbvTusl-vn16sfme7O9_Xa9WW8bzVvoG9CjoNbCCByMBS06bYF0nHKulerAUMbpMPIdGM5Myw0HPfRk2LEOWgIdu0Qfj_vWd_0pNi9ycllb71WwsWQ5CNaLFtoKiiOoU8w52VHOyU31wpISeQhZ_gtZnkN-lvpqfX86o-wma87GU6q1_-HUV1krPyYVtMtnjLV0GDipWHfEHqOvweUHXx5tknur_LKX__ti9hcGvJRd</recordid><startdate>199610</startdate><enddate>199610</enddate><creator>Hill, Gary E.</creator><creator>Pohorecki, Roman</creator><creator>Alonso, Anselmo</creator><creator>Rennard, Stephen I.</creator><creator>Robbins, Richard A.</creator><general>International Anesthesia Research Society</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>199610</creationdate><title>Aprotinin Reduces Interleukin-8 Production and Lung Neutrophil Accumulation After Cardiopulmonary Bypass</title><author>Hill, Gary E. ; Pohorecki, Roman ; Alonso, Anselmo ; Rennard, Stephen I. ; Robbins, Richard A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5296-9cf81ee9f959de9c84ce9045155caa49d13517f5b9d53d25d59c7607b34920943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aprotinin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Bronchi - pathology</topic><topic>Bronchoalveolar Lavage Fluid - immunology</topic><topic>Cardiopulmonary Bypass - adverse effects</topic><topic>Cell Culture Techniques</topic><topic>Chemotactic Factors - antagonists &amp; inhibitors</topic><topic>Chemotaxis, Leukocyte - drug effects</topic><topic>Culture Media, Conditioned</topic><topic>Hemostatics - therapeutic use</topic><topic>Humans</topic><topic>Interleukin-8 - analysis</topic><topic>Interleukin-8 - antagonists &amp; inhibitors</topic><topic>Leukocyte Count - drug effects</topic><topic>Lung - drug effects</topic><topic>Lung - pathology</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>N-Formylmethionine Leucyl-Phenylalanine - pharmacology</topic><topic>Neutrophil Activation - drug effects</topic><topic>Neutrophils - drug effects</topic><topic>Neutrophils - pathology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia - immunology</topic><topic>Protein Synthesis Inhibitors - pharmacology</topic><topic>Tosyllysine Chloromethyl Ketone - pharmacology</topic><topic>Tumor Necrosis Factor-alpha - antagonists &amp; inhibitors</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hill, Gary E.</creatorcontrib><creatorcontrib>Pohorecki, Roman</creatorcontrib><creatorcontrib>Alonso, Anselmo</creatorcontrib><creatorcontrib>Rennard, Stephen I.</creatorcontrib><creatorcontrib>Robbins, Richard A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Anesthesia and analgesia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hill, Gary E.</au><au>Pohorecki, Roman</au><au>Alonso, Anselmo</au><au>Rennard, Stephen I.</au><au>Robbins, Richard A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aprotinin Reduces Interleukin-8 Production and Lung Neutrophil Accumulation After Cardiopulmonary Bypass</atitle><jtitle>Anesthesia and analgesia</jtitle><addtitle>Anesth Analg</addtitle><date>1996-10</date><risdate>1996</risdate><volume>83</volume><issue>4</issue><spage>696</spage><epage>700</epage><pages>696-700</pages><issn>0003-2999</issn><eissn>1526-7598</eissn><coden>AACRAT</coden><abstract>Pulmonary neutrophil entrapment and resultant oxidative injury is thought to be the primary mechanism of cardiopulmonary bypass (CPB) induced lung injury.Interleukin-8 (IL-8), a potent neutrophil chemoattractant induced by cytokines, including tumor necrosis factor-alpha (TNF), is found in increased concentrations in bronchial alveolar lavage fluid (BALF) in lung inflammation. Since aprotinin reduces TNF release during CPB, the effects of aprotinin on BALF IL-8 concentrations and neutrophil levels were determined after CPB in adult humans. Study patients were equally divided into a control group (n = 8, Group 1) and an aprotinin treated group (n = 8, Group 2). In vitro neutrophil chemotaxis was done with volunteer neutrophils using three different chemoattractants1) N-formyl-1-methionyl-1-leucyl-1-phenylalanine (FMLP); 2) the supernatant of a human bronchial epithelial cell culture line, A549, after 24 h of TNF stimulation with or without aprotinin or N-alpha-tosyl-L-lysine chloromethyl ketone (TLCK) (a potent protease inhibitor), and 3) BALF. Aprotinin treatment significantly (P &lt; 0.05) reduced post-CPB BALF IL-8 concentrations and percentage of neutrophils. In vitro, BALF from Group 1 had significantly greater chemotactic ability when compared with Group 2. The TNF stimulated A549 cell culture supernatant had significantly (P &lt; 0.05) greater chemotactic ability than control supernatant, while aprotinin and TLCK significantly (P &lt; 0.05) reduced this chemotactic ability. These results demonstrate that aprotinin blunts IL-8 production and reduces neutrophil lung accumulation post-CPB.(Anesth Analg 1996;83:696-700)</abstract><cop>Hagerstown, MD</cop><pub>International Anesthesia Research Society</pub><pmid>8831305</pmid><doi>10.1097/00000539-199610000-00006</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0003-2999
ispartof Anesthesia and analgesia, 1996-10, Vol.83 (4), p.696-700
issn 0003-2999
1526-7598
language eng
recordid cdi_proquest_miscellaneous_78368292
source MEDLINE; Journals@Ovid LWW Legacy Archive; EZB-FREE-00999 freely available EZB journals; Journals@Ovid Complete
subjects Adult
Aged
Aprotinin - therapeutic use
Biological and medical sciences
Blood. Blood coagulation. Reticuloendothelial system
Bronchi - pathology
Bronchoalveolar Lavage Fluid - immunology
Cardiopulmonary Bypass - adverse effects
Cell Culture Techniques
Chemotactic Factors - antagonists & inhibitors
Chemotaxis, Leukocyte - drug effects
Culture Media, Conditioned
Hemostatics - therapeutic use
Humans
Interleukin-8 - analysis
Interleukin-8 - antagonists & inhibitors
Leukocyte Count - drug effects
Lung - drug effects
Lung - pathology
Medical sciences
Middle Aged
N-Formylmethionine Leucyl-Phenylalanine - pharmacology
Neutrophil Activation - drug effects
Neutrophils - drug effects
Neutrophils - pathology
Pharmacology. Drug treatments
Pneumonia - immunology
Protein Synthesis Inhibitors - pharmacology
Tosyllysine Chloromethyl Ketone - pharmacology
Tumor Necrosis Factor-alpha - antagonists & inhibitors
Tumor Necrosis Factor-alpha - immunology
title Aprotinin Reduces Interleukin-8 Production and Lung Neutrophil Accumulation After Cardiopulmonary Bypass
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T09%3A49%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aprotinin%20Reduces%20Interleukin-8%20Production%20and%20Lung%20Neutrophil%20Accumulation%20After%20Cardiopulmonary%20Bypass&rft.jtitle=Anesthesia%20and%20analgesia&rft.au=Hill,%20Gary%20E.&rft.date=1996-10&rft.volume=83&rft.issue=4&rft.spage=696&rft.epage=700&rft.pages=696-700&rft.issn=0003-2999&rft.eissn=1526-7598&rft.coden=AACRAT&rft_id=info:doi/10.1097/00000539-199610000-00006&rft_dat=%3Cproquest_cross%3E78368292%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=78368292&rft_id=info:pmid/8831305&rfr_iscdi=true